A Phase 1 interventional study of ABBV-8736 and Placebo in Healthy Volunteer, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive intravenous (IV) ABBV-8736 dose A every 2 weeks for a total of 3 doses.
Drug: ABBV-8736
Participants will receive IV ABBV-8736 placebo dose A every 2 weeks for a total of 3 doses.
Drug: Placebo
Participants will receive IV ABBV-8736 dose B every 2 weeks for a total of 3 doses.
Drug: ABBV-8736
Participants will receive IV ABBV-8736 placebo dose B every 2 weeks for a total of 3 doses.
Drug: Placebo
Intravenous (IV) Infusion
IV Infusion
Number of Participants with Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to Approximately 113 Days
Maximum Observed Concentration (Cmax) of ABBV-8736
Cmax of ABBV-8736.
Time frame: Up to Approximately 113 Days
Time to Cmax (Tmax) of ABBV-8736
Tmax of ABBV-8736.
Time frame: Up to Approximately 113 Days
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of ABBV-8736
AUCtau of ABBV-8736.
Time frame: Up to Approximately 113 Days
Observed plasma concentration at the end of a dosing interval (Ctrough) of ABBV-8736
Ctrough of ABBV-8736.
Time frame: Up to Approximately 113 Days
Apparent Terminal Phase Elimination Rate Constant (β) of ABBV-8736
β of ABBV-8736.
Time frame: Up to Approximately 113 Days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-8736
t1/2 of ABBV-8736.
Time frame: Up to Approximately 113 Days
Clearance (CL) for Intravenous (IV) Dosing
CL for IV dosing.
Time frame: Up to Approximately 113 Days
Immunogenicity of ABBV-8736 as Determined by Anti-Drug Antibodies (ADAs)
Incidence and concentrations of ADAs. Neutralizing ADAs (NAb) may be evaluated.
Time frame: Up to Approximately 113 Days
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2025 to primary completion in Mar 2026, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABBV-8736